

Biocept Inc

10:15 29 May 2020

Biocept's cancer mutation-detecting Target Selector platform affirmed at oncology conference

Biocept Inc (NASDAQ:BIOC) announced Friday that data validating the ability of its Target Selector platform to identify actionable mutations in the cerebrospinal fluid of cancer patients was presented at the American Society for Clinical Oncology (ASCO) 2020 Virtual Scientific Program.

The presentation showed higher sensitivity with Target Selector in detecting cancer material and identifying leptomeningeal metastases — cancer in the thin layers of tissue that cover and protect the brain and spinal cord — in cerebrospinal fluid compared with cerebrospinal fluid cytology, the standard-of-care technology.

The presence of tumor cells in cerebrospinal fluid can indicate brain metastasis, which occur when cancer spreads to the central nervous system. Biocept's Target Selector assays are able to detect circulating tumor cells (CTCs) and circulating DNA (ctDNA) and identify cancer-associated biomarkers in the cerebrospinal fluid.

READ: Biocept expands molecular assay offering with release of Target Selector BRAF kit

Identifying biomarkers is key to developing targeted therapies for patients, the company said,

"We are excited to share these data at ASCO as they support our belief that Target Selector has potential applicability for identifying actionable mutations in patients with brain metastases allowing physicians the choice to test cerebrospinal fluid, blood or both when looking for biomarker information in order to choose the most appropriate therapy," CEO Michael Nall said in a statement.

"We are planning a larger study to further validate the sensitivity of our Target Selector technology compared with cerebrospinal fluid cytology with the goal of making our platform the standard of care for leptomeningeal metastases testing," he added.

The information was presented by Kevin Kalinsky, an associate professor of medicine at Columbia University Vagelos College of Physicians and Surgeons and an oncologist at New York-Presbyterian/Columbia University Irving Medical Center.

"Cerebrospinal fluid cytology for the detection of leptomeningeal metastases is the standard, but it often results in false negative results, and lacks sensitivity in detecting biomarkers," Kalinsky said. "These results show Biocept's Target Selector is a promising tool to meet an underserved need in providing this critical information."

Cerebrospinal fluid is normally collected with a medical procedure known as a spinal tap or lumbar puncture when

Price: 4.49

Market Cap: \$60.14 m

1 Year Share Price Graph



October 2019 April 2020 October 2020

Share Information

Code: BIOC

Listing: NASDAQ

52 week High Low
13 2.118

Sector: Medical technology & services

Website: biocept.com

Company Synopsis:

Biocept, Inc. is a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both CTCs and in plasma (ctDNA).

action@proactiveinvestors.com

cancer patients present with central nervous system symptoms such as confusion or dementia, the company said.

Biocept's Target Selector offers an alternative and potentially more accurate means of detecting biomarkers from CTCs and ctDNA.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter [@andrew_kessel](https://twitter.com/andrew_kessel)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).